Trial Profile
Phase II trial of tamibarotene in combination with chemotherapy or arsenic trioxide as first-line therapy in patients with acute promyelocytic leukaemia.
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 01 Dec 2022
Price :
$35
*
At a glance
- Drugs Tamibarotene (Primary) ; Antineoplastics; Arsenic trioxide
- Indications Acute promyelocytic leukaemia
- Focus Therapeutic Use
- Sponsors LadRx Corporation
- 26 Jan 2010 New trial record.